Collectively, these data reveal a linkage between the expression levels of these three selected AATs (SLC7A5/LAT1, SLC38A2/SNAT2, and SLC1A5/ASCT2) and the oncogenic KRAS mutation status in patients with CRC. Here, KRAS is linked to colorectal carcinoma.